ALLO: רווח נקי למניה (EPS TTM) Allogene Therapeutics Inc

The development of allogeneic therapy is limited by strict FDA oversight regarding the safety of genetic modifications. The TTM net income per share distribution demonstrates the asset's current position, with the level sitting around -0.61. Allogene Therapeutics (ALLO) strives for leadership in the patent race by creating affordable CAR-T products. Meanwhile, the financial stability of Allogene Therapeutics (ALLO) relies exclusively on external capital and the success of clinical trials.

Allogene Therapeutics (ALLO) is currently in the clinical development stage without existing revenue streams, which results in negative net income per share. This indicator calculates the annual proportional income by dividing the final financial result by the number of shares, thereby measuring the rate of capital consumption. By analyzing the TTM net income per share distribution, an investor assesses the sustainability of the business model and the risks of further asset value dilution.